Mounjaro vs Saxenda: 22.5% vs 8% — Which Injection to Choose in 2026

Imagine you're facing a choice. Two weight loss products, both GLP-1 agonists, both injectable. But one requires daily shots, the other — just once weekly. One provides 8% weight loss, the other — nearly 23%. How to choose?

This is a question we receive weekly at DOZA. And honestly, the answer isn't as complex as it seems. Let's look at the numbers.

Quick Answer for Those in a Hurry

Mounjaro (tirzepatide) provides up to 22.5% weight loss over 72 weeks. Saxenda (liraglutide) — around 8% over 56 weeks. Nearly three times the difference.

Mounjaro is injected once weekly with an automatic KwikPen. Saxenda — daily, manually setting the dose. That's 52 shots vs 365 per year.

Mounjaro works through dual GIP + GLP-1 mechanism. Saxenda — only first-generation GLP-1, approved back in 2014.

Here's what's interesting: per result, Mounjaro turns out to be more economical. More on this below.

What is Saxenda and How It Works

Saxenda is liraglutide at 3 mg dose, developed by Novo Nordisk. FDA approved this product in 2014, and at the time it was a real breakthrough: the first GLP-1 agonist specifically for weight management.

The mechanism is simple. Liraglutide mimics the satiety hormone GLP-1, which is produced in the intestine after eating. When you inject Saxenda, the brain receives a signal: "We're full". Appetite decreases, portions become smaller.

In the large SCALE study, participants lost an average of 8% initial weight over 56 weeks [5]. For a 100 kg person, that's minus 8 kilograms. Noticeable result, but not revolutionary.

Here's what's important to understand: Saxenda requires daily injections. Moreover, the dose needs gradual escalation over the first five weeks: from 0.6 mg to target 3 mg. That's five steps per week.

Mounjaro: What Changed in 10 Years

Mounjaro (tirzepatide) from Eli Lilly is already a different generation. Approved in 2022, it works through two receptors simultaneously: GIP and GLP-1.

Why is this important? GLP-1 reduces appetite. GIP improves insulin sensitivity and affects fat tissue metabolism. Together they provide synergistic effect that no single-agent can achieve.

SURMOUNT-1 study results are impressive. Participants on maximum 15 mg dose lost 22.5% initial weight over 72 weeks. For a 100 kg person, that's minus 22.5 kilograms.

And another detail: Mounjaro is injected only once weekly. The automatic KwikPen makes the process maximally simple.

As you can see, Mounjaro surpasses Saxenda in virtually every criterion. But let's examine the most important points in detail.

Effectiveness: -22.5% vs -8% — What This Means in Practice

Numbers in tables can seem abstract. So let's imagine a specific person.

Marina, 42 years old, weight 95 kg. Goal — lose weight to 75 kg.

On Saxenda over 56 weeks she'll lose approximately 8% weight, i.e. 7.6 kg. Final weight — 87.4 kg. Still far from goal.

On Mounjaro over 72 weeks she can lose up to 22.5%, i.e. 21.4 kg. Final weight — 73.6 kg. Goal achieved and even exceeded.

By the way, tirzepatide outperforms not only liraglutide, but also other modern GLP-1 products. In the SURPASS-2 study, Mounjaro was compared with semaglutide (the active ingredient in Ozempic). The result: tirzepatide provided a weight loss of 12.4 kg versus 6.2 kg on semaglutide [2].

Mounjaro is an automatic KwikPen. Press button — done. No need to set dose, count units, worry about accuracy.

Saxenda is a classic pen with manual dose setting. Daily. 365 days per year. For many, this becomes a reason to discontinue the program.

Another real indicator: in a study of non-diabetic patients taking GLP-1 for weight loss, highest adherence was with weekly injectable products, lowest — with daily ones [3].

Side Effects: Less Nausea with Better Results

Both products can cause gastrointestinal reactions. This is normal, as the mechanism of action involves impact on the digestive system. But there's a difference.

Saxenda causes nausea in 39% of people. Almost every second person. Moreover, due to daily administration, the body constantly receives new doses, and adaptation may take longer [5].

Mounjaro — nausea in 17-24% of cases, usually mild or moderate [2]. And importantly: symptoms usually appear during dose escalation and resolve within 2-4 weeks.

The 15-22 percentage point difference in nausea is significant. And this is another argument for Mounjaro: better results with less discomfort.

If after this comparison you still lean towards semaglutide as an intermediate step before Mounjaro — Buy Ozempic in Ukraine directly through DOZA: original Ozempic FlexTouch from Novo Nordisk (0.25 / 0.5 / 1 mg), thermobox 2–8 °C with temperature sensor, verified serial number. Express delivery Kyiv/Lviv/Dnipro in 1–2 hours or Nova Poshta 1–2 days. Before starting the course — free consultation with a DOZA specialist.

Treatment Adherence: Why This is Critical

You can have the most effective product in the world. But if a person quits the program in the second month, there will be no result.

Real clinical practice studies confirm this. In a cohort of over 4,000 non-diabetic people taking GLP-1 for weight loss, only 27.2% remained adherent to therapy during the first year [3].

But there's an important detail: highest adherence was observed with weekly injectable products, lowest — with daily ones [3].

In another study, people on weekly dulaglutide had 3.2 times higher chances of following instructions than on daily oral semaglutide [4].

Where to Order Mounjaro in Ukraine

Ready to start the course? Buy Mounjaro in Ukraine in the DOZA catalog — all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) with official thermal delivery within 24 hours and 24/7 specialist support. Current Mounjaro prices 2026 — from 1,000 ₴ for a test dose or 8,000 ₴/month for a full program with monitoring.